Stock Update (NASDAQ:ONCY): Oncolytics Biotech, Inc. (USA) Announces Start of Enrollment in Phase 1b Study of Multiple Myeloma Looking at REOLYSIN® in Combination with Bortezomib
Oncolytics Biotech, Inc. (USA) (OTCMKTS:ONCYF) announced that enrollment has commenced in a Phase Ib study of REOLYSIN® combined with standard doses of bortezomib (Kyprolis®) and dexamethasone in patients with relapsed or refractory multiple myeloma (REO 019).Kevin Kelly, M.D., Ph.D. of the Keck School of Medicine of the University of Southern California (USC), is the principal investigator.
“We recently announced promising early results from another multiple myeloma study examining REOLYSIN® in combination with carfilzomib,” said Dr. Brad Thompson, President and CEO of Oncolytics. “Our goal is to determine how REOLYSIN® performs with the standard of care options in this difficult to treat indication and then take the best combination forward into later-stage testing.”
The study is a two-stage open-label Phase Ib trial of adult patients with relapsed or refractory multiple myeloma following at least one line of therapy. The study objectives include determining the maximum tolerated dose (“MTD”) and the safety profile of REOLYSIN® in combination with bortezomib and dexamethasone, as well as exploring the toxicities and the pharmacodynamics of the treatment combination, and determining the preliminary response rate in patients with relapsed or refractory multiple myeloma.
Adult patients will receive REOLYSIN® on days 1, 2, 8, 9, 15 and 16 of each 28-day cycle. Patients will also receive bortezomib and dexamethasone on days 1, 8 and 15.The first stage of the study will enroll three to six patients in each of two cohorts, with each cohort at a different dose level. The second stage of the study will enroll up to 12 patients at the MTD reached in the first stage. (Original Source)
Shares of Oncolytics Biotech closed last Wednesday at $0.33. ONCY has a 1-year high of $1.40 and a 1-year low of $0.24. The stock’s 50-day moving average is $0.39 and its 200-day moving average is $0.55.
Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer.